Year: 2022

ImmuPharma (LSE:IMM) (Euronext Growth Brussels: ALIMM), announces that on 11 June 2020, Dr Robert Zimmer, a Director of the Company, transferred 20,000,000 ordinary shares of 10 pence each (“Ordinary Shares”) to Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder. For full information click here

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities (“Securities”) and associated options (“Options”).…

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (“MAR”).

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that the Company’s Annual General Meeting (AGM) confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19 Guidance rules still apply, as set out in the announcement issued on…

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2019, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…

Click here for information IMM RNS Form TR1 Lanstead 18 May 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company provides a progress update on activities around Covid-19.  On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’ programs, one of which was in ‘Antivirals’. Investigation of the application of the Ureka peptide technologies…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts (“Report”) for the year ended 31 December 2019, has today been published on the Company’s website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in…

ImmuPharma plc (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019 (the “Period”).  Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £1.4 million (31 December 2018:  £4.9…

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced (30/3/20) £1.5 million Subscription and update on the Company’s R&D programmes, via the ‘Investor Meet Company’ platform. The live…